GUARDANT HEALTH, INC. vs RadNet, Inc., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Both diagnostics operators lose money, and the losses could not be less alike: Guardant's negative 40.2% operating margin is chosen, R&D and commercial spend toward cancer-screening dominance, while RadNet's negative 4.2% is structural, imaging-center economics under wage and rate pressure. The market prices intent over accident by a factor of four, $20B against $5B. RadNet generates real cash despite the losses, a 7.2% free-cash yield from depreciation-heavy accounting; Guardant burns modestly against a 4.7 current ratio war chest. Neither has an earnings multiple. One loss is a strategy with a prize attached; the other is a business model doing its best; the valuations grade the difference unsentimentally.
Comparison updated 2026-07-10.
| Metric | GH | RDNT |
|---|---|---|
| Price | $149.32 | $60.71 |
| Market cap | $19.6B | $4.7B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/B | — | 3.46 |
| P/S | 18.15 | 2.18 |
| EV/EBITDA | — | 23.8 |
| Revenue growth | +39.3% | +14.7% |
| Operating margin | -40.2% | -4.2% |
| Net margin | -40.1% | -0.7% |
| Return on equity | — | -1.1% |
| Return on assets | -22.6% | -0.4% |
| Return on invested capital | -26.7% | 2.0% |
| FCF yield | -1.2% | 7.2% |
| Debt / equity | — | 0.82 |
| Current ratio | 4.68 | 1.17 |
| Altman Z (solvency) | 4.37 | 1.63 |
| Piotroski F (quality) | 3 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.